Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
5106 studies found for:    University of Maryland, Baltimore
Show Display Options
RSS Create an RSS feed from your search for:
University of Maryland, Baltimore
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  The Therapeutic Workplace Intervention in Community Settings
Conditions: Drug Abuse;   Alcohol Abuse
Intervention: Behavioral: Community Therapeutic Workplace
2 Unknown  Treatment for Men Who Are Abusive to Their Partners
Condition: Domestic Violence
Intervention: Behavioral: Individual Cognitive Behavioral Therapy
3 Active, not recruiting Regulation of Endothelial Progenitor Cells by Short-Term Exercise
Conditions: Aging;   Exercise;   Cardiovascular Disease
Interventions: Other: Exercise Training;   Other: Exercise Cessation
4 Terminated Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection: Phase IIa
Condition: Shigella
Interventions: Biological: CVD 1208S, a Shigella flexneri 2a live, oral vaccine;   Other: Placebo
5 Completed Safety and Efficacy Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella Infection Using cGMP
Condition: Shigella
Interventions: Biological: CVD 1208S, a Shigella flexneri 2a live, oral vaccine;   Other: Placebo
6 Unknown  Safety and Immunogenicity of CVD 1902 Oral Attenuated Vaccine to Prevent S. Paratyphi A Infection
Condition: Salmonella
Interventions: Biological: CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine;   Other: Placebo
7 Terminated Safety and Efficacy Challenge Study of CVD 1208S, a Live, Attenuated Oral Vaccine to Prevent Shigella: Phase IIb
Condition: Shigella
Intervention: Biological: CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a
8 Completed Bupivacaine Versus Lidocaine on Inflammatory Regulation Following Endodontic Surgery
Condition: Pain
Interventions: Drug: Lidocaine;   Drug: Bupivacaine
9 Unknown  Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients
Conditions: Schizophrenia;   Mood Disorders;   Substance Dependence
Interventions: Behavioral: Behavioral Treatment for Substance Abuse in SPMI (BTSAS);   Behavioral: Supportive Treatment in Addiction Recovery (STAR);   Behavioral: Critical Time Intervention (CTI)
10 Not yet recruiting Dose Response of Epinephrine
Condition: Diabetes Complications
Interventions: Drug: Epinephrine;   Other: Saline infusion
11 Not yet recruiting TMS for Symptom Reduction in Schizophrenia
Condition: Schizophrenia and Related Disorders
Interventions: Device: Active rTMS stimulation;   Device: Sham rTMS stimulation
12 Recruiting CNS Sarcoidosis and Acthar Gel
Condition: CNS Sarcoidosis
Intervention: Drug: H.P. Acthar Gel
13 Recruiting GLP-1 and Hypoglycemia
Condition: Type 2 Diabetes Mellitus
Interventions: Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion;   Other: Placebo Comparator: Saline Infusion
14 Recruiting Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus (DM)
Conditions: Type 1 Diabetes;   Hypoglycemia Associated Autonomic Failure
Interventions: Drug: Fluoxetine;   Drug: Placebo control
15 Completed
Has Results
Enhanced Room Cleaning in Intensive Care Units to Reduce Gown and Glove Contamination With Multi-drug-resistant Bacteria
Condition: Infection Control
Interventions: Other: Enhanced cleaning of surfaces in ICU rooms;   Other: Sham enhanced cleaning of surfaces in ICU rooms
16 Completed Mobile Diabetes Management
Condition: Diabetes
Interventions: Device: Tailored Patient Intervention;   Device: Patient-physician intervention;   Device: Patient and PCP intervention with analyzed data
17 Active, not recruiting Effects of Galantamine on Cognition
Condition: Schizophrenia
Interventions: Drug: Galantamine;   Drug: Galantamine or Placebo
18 Recruiting Hypoglycemia Associated Autonomic Failure in Type 1 Diabetes Mellitus
Condition: Type 1 Diabetes
Interventions: Drug: Dehydroepiandrosterone;   Drug: Placebo
19 Terminated
Has Results
Mechanisms of Ramipril Reduction in the Onset of Type 2 Diabetes
Condition: Metabolic Syndrome
Interventions: Drug: Ramipril;   Drug: HCTZ-hydrochlorothiazide;   Drug: Ramipril+HCTZ
20 Active, not recruiting Mechanisms of Hypoglycemia Associated Autonomic Dysfunction Question 2
Condition: Type 1 Diabetes
Interventions: Drug: Alprazolam;   Drug: Placebo

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.